Abstract Genetic hypercalciuric stone-forming (GHS) rats, bred to maximize urine (u) calcium (Ca) excretion, demonstrate increased intestinal Ca absorption, increased bone Ca resorption, and reduced renal Ca reabsorption, all leading to elevated uCa compared to the parental SpragueDawley (SD) rats. GHS rats have increased numbers of vitamin D receptors (VDRs) at each site, with normal levels of 1,25(OH) 2 D 3 (1,25D), suggesting their VDR is undersaturated with 1,25D. We have shown that 1,25D induces a greater increase in uCa in GHS than SD rats. To examine the effect of the increased VDR on the osseous response to 1,25D, we fed GHS and SD rats an ample Ca diet and injected either 1,25D [low dose (LD) 12.5 or high dose (HD) 25 ng/100 g body weight/day] or vehicle (veh) daily for 16 days. Femoral areal bone mineral density (aBMD, by DEXA) was decreased in GHS?LD and GHS?HD relative to GHS?veh, while there was no effect on SD. Vertebral aBMD was lower in GHS compared to SD and further decreased in GHS?HD. Both femoral and L6 vertebral volumetric BMD (by lCT) were lower in GHS and further reduced by HD. Histomorphometry indicated a decreased osteoclast number in GHS?HD compared to GHS?veh or SD?HD. In tibiae, GHS?HD trabecular thickness and number increased, with a 12-fold increase in osteoid volume but only a threefold increase in bone volume. Bone formation rate was decreased in GHS?HD relative to GHS?veh, confirming the mineralization defect. The loss of BMD and the mineralization defect in GHS rats contribute to increased hypercalciuria; if these effects persist, they would result in decreased bone strength, making these bones more fractureprone. The enhanced effect of 1,25D in GHS rats indicates that the increased VDRs are biologically active.
Introduction
Hypercalciuria is the most common metabolic abnormality in patients with nephrolithiasis [1] . The increased urine (u) calcium (Ca) excretion leads to increased urine supersaturation (SS) with respect to the solid phases of calcium hydrogen phosphate (CaHPO 4 , brushite) and calcium oxalate (CaOx), which enhances the probability of nucleation and growth of crystals into clinically significant stones [1] . In humans, idiopathic hypercalciuria (IH) is characterized by increased intestinal Ca absorption and/or decreased renal tubule Ca reabsorption, resulting in hypercalciuria with normal serum Ca (sCa), normal or elevated serum 1,25(OH) 2 D 3 (s1,25D), normal serum parathyroid hormone (sPTH), normal or low serum phosphate (sP), and low bone mass [1] [2] [3] . IH is often familial with a pattern consistent with a polygenic mode of inheritance [2] [3] [4] .
We have established a strain of hypercalciuric rats by selectively inbreeding the most hypercalciuric SpragueDawley (SD) rats to maximize uCa excretion . After more than 90 generations of continuous selection and inbreeding, each rat consistently excretes *8-to 10-fold more uCa than the SD controls [14, 32] and forms kidney stones [5, 7, 8, 16, 18, 20, 23, 25-28, 30, 31] . These hypercalciuric rats have been termed ''genetic hypercalciuric stone-forming'' (GHS) rats .
GHS rats exhibit many features of human IH, including normal sCa [6, 10, 12, 15, 21, 22, 29] , increased intestinal Ca absorption [12] and bone resorption [11] , decreased renal tubule Ca reabsorption [13] , normal s1,25D levels [6, 10, 12, 15, 21, 22, 29] , and a polygenic mode of inheritance [19] . GHS rats have elevated levels of vitamin D receptor (VDR) protein in Ca transporting organs including the kidney, intestine, and bone [11] [12] [13] 33] .
In humans the changes in intestine, kidney, and bone Ca transport in IH may be reproduced by administration of 1,25D to normal volunteers, leading to hypercalciuria [34, 35] . The increase in human uCa with 1,25D implies that the effect of 1,25D to increase intestinal Ca absorption [36] and bone Ca resorption [34, 35] overwhelms any 1,25D-mediated increase in renal tubular Ca reabsorption [37] . While elevated s1,25D levels may account for the phenotype in some patients [38] [39] [40] [41] , most patients with IH have normal s1,25D levels [42] . High VDR levels have been found in male IH stone-formers in at least one study [43] , suggesting that elevated VDR levels may play a role in hypercalciuria in human stone-formers.
Since GHS rats have normal levels of s1,25D [6, 10, 12, 15, 21, 22, 29] , their elevated tissue levels of VDR [11] [12] [13] 33] should be relatively undersaturated with 1,25D compared to SD rats. In spite of the relative undersaturation, GHS rats have Ca transport and bone abnormalities that are consistent with a greater number of biologically active VDRs, leading to an enhanced response to vitamin D. Specifically, GHS rats have decreased bone mineral density (BMD) with reduced trabecular volume, mineralized volume, and thickness; and their bones are more brittle and fracture-prone [9, 14] . We have recently demonstrated that additional 1,25D administered for 2 weeks, which should lead to greater VDR saturation and activation, increases uCa to a greater extent in GHS than in SD rats [32] . We hypothesized that at least a portion of this increased uCa was from bone mineral stores and that GHS rats given additional 1,25D would exhibit a further decrease in BMD compared to similarly treated SD rats, compounding the intrinsic bone defects in GHS rats.
Materials and Methods

Animals
GHS rats were derived from SD rats (Charles River Laboratories, Kingston, NY) by successively inbreeding the most hypercalciuric progeny of each generation . Eight-week-old male GHS rats from the ninety-fourth generation and 8-week-old male SD rats (Charles River Laboratories) were used in this study.
Experimental Conditions
On day 0, 20 SD and 20 GHS rats were placed in metabolic cages, fed 13 g/day normal-Ca diet (1.2 % Ca; HarlanTeklad, Indianapolis, IN), and given deionized, distilled water ad libitum. By random allocation, starting on day 0, eight SD and eight GHS rats were injected daily with 5 % glucose alone (veh), four SD and four GHS rats were injected with 12.5 ng/100 g body weight 1,25D [low dose (LD); American Regent, Shirley, NY] in 5 % glucose, and eight SD and eight GHS rats were injected with 25 ng/ 100 g body weight 1,25D [high dose (HD)]. The higher dose of 1,25D was utilized as it elicits a maximal physiologic response in normal rats [21] . Starting on day 8, urine was collected for two 24-h periods. At 10 and 2 days before death, rats were injected with calcein (10 mg/kg body weight; Sigma, St. Louis, MO) for dynamic histomorphometric analysis. On days 14-16 of the study, rats were anesthetized and blood was collected by cardiac puncture. Rats were killed and femora, humeri, vertebrae, and tibiae were removed. Any animal that ate \10 g/day food or drank \15 mL/day water would have been excluded from further analysis; however, all rats met these prespecified criteria during the entire study. All procedures were approved by the University Committee for Animal Resources.
Urine and Serum Chemistries
Urine Ca and P were measured spectrophotometrically using a Beckman CX5 Pro autoanalyzer (Beckman Instruments, Brea CA) on the two urine collections, and the results for each rat were averaged. Change in uCa (DuCa) was estimated by pairing each SD?1,25D rat with a randomly assigned SD?veh rat, and each GHS?1,25D with a GHS?veh rat and calculating the difference. Serum Ca and P were determined colorimetrically (BioVision, Milpitas, CA). Serum PTH was determined by enzyme immunoassay for intact PTH (ALPCO, Salem, NH). We have used these methods previously [14, 16, 30] . Serum osteocalcin (OCN) was measured by enzyme immunoassay (ALPCO).
Bone Specimen Processing
The left tibia of each rat was cleaned of surrounding tissues, bisected, and fixed in 70 % ethanol. Fixed specimens were dehydrated through increasing concentrations of acetone (70, 90, 100, and 100 %), infiltrated in increasing strengths of Spurr/acetone solutions (50, 80, 100, and 100 %), and finally embedded in Spurr resin. Sagittal sections, 5 and 7 lm, were cut on a rotary microtome (RM2265 microtome; Leica Microsystems, Richmond Hill, Canada) using a tungsten carbide knife for histomorphometric analysis. The right tibia of each rat was cleaned of soft tissues, bisected, fixed in 10 % neutral buffered formalin, and decalcified in 0.5 M EDTA (pH 7.4). Decalcified specimens were dehydrated through a series of ethanol and xylene and embedded in paraffin. The 5-lm sagittal sections were cut on a Reichert-Jung (Boston, MA) 2030 microtome and stained for analysis.
Bone Mineral Density
Areal BMD (aBMD) of the L5 vertebrae, left femora, and left humeri were determined using dual-energy X-ray absorptiometry (DEXA) on a Lunar PIXImus Bone Densitometer (Lunar GE, Mississauga, Canada) designed for small-animal bone analysis. Volumetric BMD (vBMD) and bone microarchitecture of the L6 vertebrae, right femora, and right humeri were determined using the 1174 compact Micro-CT (Skyscan, Kontich, Belgium). Femora, humeri, and vertebrae were scanned in saline-soaked gauze at a voxel size of 20.9 or 9.1 lm with the following setting: X-ray voltage = 50 kV, X-ray current = 800 lA, frame averaging = 2. Bone structure was quantified per the American Society for Bone Mineral (ASBMR) nomenclature and guidelines [44] . Reconstructed images obtained from the scanner were analyzed using the Skyscan CT-Analyzer software (version 1.5.0).
Biomechanical Testing
Three-point bending was performed on the excised right humeri of all rats to test the mechanical properties of cortical bone. The bone was tested 2 mm distal from the midpoint using a gauge length of 10 mm. Vertebral compression was performed on the excised L6 vertebrae of all rats to test the mechanical properties of trabecular bone undergoing a constant compressive stress. All biomechanical tests were performed on the Instron 4465 mechanical testing machine (Instron, Burlington, Canada). Load versus time data were collected every 0.1 s using LabView 5.0 data acquisition software (National Instruments, Austin, TX).
Histomorphometry
Static histomorphometry was performed on undecalcified Goldner's trichrome-stained sections (5 lm) of the left proximal tibia. A semiautomated image analysis system (Bioquant Image Analysis, Nashville, TN) was used to quantify bone structure per the ASBMR nomenclature and guidelines [45, 46] . We determined the trabecular bone volume (BV), osteoid volume (OV), osteoid surface (OS), osteoid thickness (O.Th), and eroded surface (ES); trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp) were also calculated. Unstained sections (7 lm) of undecalcified left proximal tibiae were used to evaluate bone formation through the use of calcein green labeling injected at 10 and 2 days prior to death. The osteoid maturation time (OMT) is the osteoid width divided by the distance between labels per day. Mineralization lag time (MLT) is OMT adjusted for the percentage of osteoid surface that has a calcein label. To assess osteoclast number and activity, 5-lm decalcified sections of the right proximal tibia were stained for tartrate-resistant acid phosphatase (TRAP) as an indirect indicator of bone resorption by measuring osteoclast number and osteoclast surface.
Statistics
All histologic and biomechanical data were analyzed using the SPPS Statistics 20 program (SPSS, Chicago, IL). The treatment groups were tested for significance using oneway analysis of variance (ANOVA) and the Tukey or Games-Howell post hoc test, as appropriate. All serum and urine data were analyzed using Statistica with the one-way ANOVA and the Bonferroni test for multiple comparisons. p B 0.05 was considered significant.
Results
Serum and Urine Chemistry
There was no difference in sCa, sP, sPTH, or sOCN between SD?veh and GHS?veh (Fig. 1) . Injection of 12.5 ng 1,25D (LD) significantly increased sCa levels in SD and in GHS rats, while injection of 25 ng 1,25D (HD) further increased sCa in SD but not in GHS. Injection of LD increased sP in SD but not in GHS; however, injection of HD did not increase sP in either strain. While injection of LD and HD lowered sPTH significantly in SD, sPTH was reduced numerically, but not significantly, in GHS. Injection of LD did not significantly alter sOCN in SD but did increase sOCN in GHS, while injection of HD increased sOCN in SD and in GHS. Injection of HD did not further increase sOCN in GHS compared to LD.
In the absence of exogenous 1,25D, uCa was significantly higher in GHS than in SD rats ( Fig. 2) , as we have previously reported . LD increased uCa in both GHS and SD rats, and GHS?LD excreted significantly more uCa than SD?LD. HD also increased uCa in both GHS and SD rats; GHS?HD excreted significantly more uCa than SD?HD but not more uCa than GHS?LD. While administration of 1,25D increased uCa in all groups, there was a greater increase in the GHS?HD (DuCa = 32.5 ± 1.5 mg/day) than in the SD?HD group (DuCa = 22.6 ± 1.5 mg/day; p = 0.011), confirming that administration of 1,25D results in a greater increase in biological activity, as measured by the increase in uCa, in GHS than in SD rats, perhaps due to the increased number of VDRs in GHS rats.
Bone Mineral Density aBMD (by DEXA) in GHS?veh rats was lower than that of SD?veh in the vertebrae, while vBMD (by lCT) in GHS?veh rats was lower than that of SD?veh in both the femora and vertebrae (Fig. 3) . In SD, only femoral vBMD was decreased by 1,25D, while in GHS 1,25D decreased both aBMD and vBMD in the femora as well as in the vertebrae.
Bone Structure
Trabecular bone structure was examined in two skeletal sites: L6 vertebrae and the metaphysis of the left proximal tibiae.
lCT Based on lCT analysis of the L6 vertebrae, neither LD nor HD affected trabecular bone volume in SD rats; however, HD significantly decreased trabecular bone volume in GHS rats compared to similarly treated SD rats (Table 1) . GHS rats had significantly decreased trabecular thickness than SD rats with vehicle alone and with HD. There were no differences in trabecular number or separation.
Histomorphometry Classic histomorphometry was performed on sagittal sections of the left proximal tibia Fig. 1 (Fig. 4) . In contrast to lCT analysis of the L6 vertebra, GHS?HD resulted in a threefold increase in tibial trabecular bone volume (BV/TV) compared to SD?HD (Fig. 5) . The increase in BV/TV in GHS?HD was primarily due to a 12-fold increase in osteoid volume (OV/BV) and a substantial increase in osteoid surface (OS/BS). The increase in osteoid leads to a corresponding increase in Tb.Th and Tb.N and reduced Tb.Sp. These results suggest that GHS, but not SD, rats exhibit a mineralization defect when given HD and that this mineralization defect is most likely responsible for the widened osteoid seam detected in histology (Fig. 4) . The growth plates of the left proximal tibiae were measured in the GHS?veh and GHS?HD rats. In addition to an increase in osteoid volume and thickness, HD 1,25D thickened the growth plates in GHS rats (GHS?veh = 271 ± 4 lm vs. GHS?HD = 359 ± 12, p \ 0.001). We suspect that deficient mineralization of the growth plate cartilage caused the growth plate cartilage to accumulate, thus thickening the growth plate.
We used calcein labeling as a marker for bone formation (Fig. 6a) . There was a significant decrease in bone formation rate/bone volume (BFR/BV) in the GHS?HD group compared to the SD?veh and GHS?veh groups (Fig. 6b) , consistent with impaired mineralization in GHS?HD rats.
We examined additional histomorphometric parameters to further investigate the impaired mineralization. We found that MLT was significantly increased and the growth plates were significantly thicker in GHS?HD rats (Fig. 6c) . Together, these histomorphometric changes indicate conclusively that HD 1,25D induced osteomalacia in GHS rats within the 2-week treatment period. TRAP analysis was used as a marker for mature osteoclasts and, indirectly, bone resorption. We examined decalcified sagittal sections of the right proximal tibia (Fig. 7a) . GHS?HD rats had a significantly lower osteoclastic surface per millimeter of bone surface (Oc.S./BS) as well as a significantly lower number of osteoclasts per millimeter of bone surface (N.Oc/BS) compared to GHS?veh (Fig. 7b ). There were no differences in any group in the number of measured osteoclasts per millimeter of osteoclast surface (N.Oc/Oc.S). Fig. 4 Effect of 1,25D on mineralized bone compared to unmineralized osteoid in SD and GHS rats. Sagittal sections of undecalcified rat tibia stained with Goldner's trichrome at 9100 (upper panel in each group) and 9250 magnification (lower panel for each group) to differentiate between mineralized bone (blue-green) and unmineralized osteoid (red). Results are quantitated in Fig. 5 . SD Sprague-Dawley, GHS genetic hypercalciuric stoneforming, LD low dose, HD high dose
Mechanical Properties
Cortical bone mechanical properties were evaluated by three-point bending of the right humeri. There were no significant differences in cortical bone mechanical properties between SD and GHS rats with or without 1,25D treatment (Table 2) .
Trabecular bone mechanical properties were measured by compression of the L6 vertebrae. Although there were no differences in ultimate stress, vertebrae from GHS rats (with and without 1,25D) tended to fail at a lower strain and required less energy to fail (toughness) than vertebrae from SD rats (Table 3) . However, there were no differences in toughness and modulus after normalizing for vertebral geometry. GHS rats had significantly smaller vertebral cross-sectional areas than SD rats, and HD further reduced the vertebral cross-sectional area in GHS rats.
Discussion
GHS rats have decreased bone quality relative to the parental SD strain [9, 14] . We have postulated that since GHS rats have normal levels of s1,25D, their elevated tissue levels of VDR in the Ca transporting organs, the intestine [12] , bone [11] , and kidney [13] , would be relatively undersaturated with 1,25D compared to SD?veh rats. Yet GHS rats have Ca transport abnormalities that are consistent with increased vitamin D signaling, implying that more 1,25D, leading to greater VDR saturation, would have a larger effect on Ca transport in GHS than in SD rats. We demonstrated that administration of 1,25D results in a greater biological response, as manifested by a larger increment in hypercalciuria in GHS compared to SD rats [32] . We hypothesized that more fully saturating the VDR in GHS by administration of 1,25D would not only exacerbate the hypercalciuria but also lead to a decline in bone quality.
We previously reported that GHS rats have a lower BMD than SD rats [9] , which was confirmed in the current study. We used the femur and humerus to investigate the quality of cortical bone and the vertebra and proximal tibia to investigate bone quality changes in the trabecular compartment. We now demonstrate that high-dose 1,25D caused a greater decrease in both cortical and trabecular BMD in GHS than in SD rats. The decrease in BMD may be responsible for a reduction in measured mechanical properties of GHS rat bones. In our study we evaluated BMD by DEXA and lCT. DEXA provided aBMD of excised whole bones, while lCT provided vBMD that was based on thresholding of pixel intensity. High-dose 1,25D may have a more significant effect on trabecular BMD than cortical BMD. Interestingly, the cross-sectional area of the L6 vertebrae of GHS rats was consistently smaller than that of SD rats, and high-dose 1,25D treatment further reduced L6 vertebral area. The rats used in this study were 8 weeks of age, and perhaps high-dose 1,25D stunted the growth of these rats, leading to smaller vertebrae. We used classic histomorphometric techniques to examine changes in bone turnover and architecture that might be responsible for the observed decrease in vertebral BMD in GHS?HD. We expected GHS?HD to have a decrease in trabecular BV, but we observed the opposite; there was almost a threefold increase in BV in GHS compared to SD?HD rats. However, this increase in BV was due to a significant increase in osteoid. GHS?HD exhibited an osteomalacic phenotype that suggests a possible delay in mineralization or a mineralization defect. This suggestion was confirmed by examination of calcein green labeling in thin sections of undecalcified left proximal tibia under UV light. GHS?HD showed a marked decrease in calcein labeling compared to SD?HD. Treatment with 1,25D at the lower dose had the same effect but to a lesser degree.
Similar to what we report here (Fig. 6) , Lieben et al. [47] found that injection of 1,25D into mice for 1 week caused an increase in the deposition of osteoid and disorganized calcein staining. Expression of the mineralization inhibitor osteopontin was increased in femoral RNA. Mice with VDR inactivation via Dmp-1-cre, specific for the mature osteoblast/osteocyte lineage, were insensitive to these effects of 1,25D. Mineralization of bone cell cultures was inhibited by addition of 1,25D to the culture medium; this inhibition could be reversed with alkaline phosphatase, suggesting that osteoblast-produced pyrophosphate was integral to this inhibition. Osteoblastic expression of components of pyrophosphate synthesis and transport [ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1), endoplasmic reticulum ENPP3, and progressive ankylosis (ANK)] were all increased by 1,25D. Our findings together with those of Lieben et al. [47] are consistent with a model where the increased number of VDRs in GHS osteoblasts and osteocytes imparts a greater sensitivity to the mineralization inhibitory activities of 1,25D, explaining the much larger accumulation of osteoid in GHS?HD than SD?HD. As of now, we have only examined VDR expression in cultures of GHS calvarial cells, which include osteoblasts at various stages of maturation and probably some osteocytes [48] . It will be of interest to confirm increased VDR expression in osteocytes from GHS bone.
To investigate the effects of high-dose 1,25D on osteoclastic activity, we examined TRAP-stained decalcified sections of the right proximal tibia. Based on previous in vitro data [11] , we expected an increase in osteoclastic activity. Unexpectedly, we found a decrease in number of osteoclasts per bone surface (N.Oc./BS) and osteoclastic surface per bone surface (Oc.S./BS) in GHS?HD. We did not observe a change in osteoclast numbers when normalized to the amount of osteoclast surface in any group. Perhaps there truly was no change in osteoclast numbers/ activity or perhaps the increase in bone resorption previously reported in GHS rats [11] was masked by the uncoupled increase in osteoblast activity and mineralization defect. Since mature osteoclasts adhere to mineralized bone, the accumulation of unmineralized osteoid may have interfered with osteoclast attachment. It is also possible that our treatment duration of 2 weeks was not long enough to maximize osteoclastic activity in the bone remodeling period, which spans an average of 4-5 weeks. High-dose 1,25D treatment suppresses the maturation of osteoclasts by reducing the RANKL/OPG ratio in osteoblasts overexpressing VDR [49] . There may also be a decrease in osteoclasts and/or osteoclast activity due to undermineralization of the newly formed bone. The rats used in this study began treatment at 8 weeks of age. The skeletons of these rats were still rapidly growing, which may account for the drastic effect of 1,25D on osteoblastic activity. Bone formation may have been increased as a result of increased calcium absorption in these growing animals; however, bone matrix deposition may have been increased to a higher rate than bone mineralization or bone mineralization may have been delayed due to an unknown mechanism that resulted in an osteomalacic phenotype. Osteomalacia has been defined by various investigators as increased osteoid volume, increased osteoid maturation time, or increased MLT. Parfitt [50] defined osteomalacia in patients with malabsorption when they had a combination of osteoid volume/bone volume [10 %, osteoid thickness [12.5 lm, and MLT [100 d; however, there are no such definitions for osteomalacia in rats. The increase in MLT along with the increase in osteoid volume and thickness are definitive markers of osteomalacia.
Based on previous studies [9, 14] , we expected GHS rats to have weaker and more brittle bones than SD rats and that treatment with 1,25D would further compound the intrinsic bone defects in GHS rats. We did not observe a difference in cortical bone mechanical properties in GHS rats regardless of 1,25D treatment. We did not anticipate a change in the cortical compartment due to the slow turnover rate of cortical bone. The trabecular compartment has a faster turnover rate, and several trends were observed in the vertebrae during biomechanical testing. In vertebral compression testing GHS rat vertebrae required less energy to fail and were stiffer than those of SD rats given the same treatment; however, this trend disappeared after normalizing for vertebral geometry. In other words, the vertebral bodies of GHS rats were easier to break and more brittle than those of SD rats given the same treatment (Table 3) , but this was most likely due to structural differences rather than material differences. There were no statistical changes in bone mechanical properties in the humerus or vertebrae in this study, which may be a result of the shorter treatment duration compared to our previous studies. Our current study had a treatment duration of only 2 weeks rather than 6-18 weeks [9, 14] . If the treatment duration was extended to 6-18 weeks, perhaps the observed trends in the All data are presented as mean ± standard deviation SD Sprague-Dawley, GHS genetic hypercalciuric stone-forming, LD low dose, HD high dose reduction of vertebral toughness would become statistically significant. Furthermore, the rats used in this study were 8 weeks of age at the onset of treatment. Perhaps treatment with exogenous 1,25D for 2 weeks at this stage in the growing rat skeleton was sufficient to cause structural differences during development but insufficient to cause material differences. We used two doses of 1,25D to determine if there was a dose dependence for this hormone on the measured parameters. While BV increased with increasing dose, the differences in other parameters (e.g., uCa, BFR/BV, sOCN), though trending toward a greater effect with HD than LD, did not reach significance. The lack of significance may reflect the smaller sample size in the LD groups (n = 4) compared to the veh and HD groups (both n = 8) or may indicate that even LD elicited the maximal response in GHS. It is important to point out that although we have no mechanistic explanation for the osteoid increase in GHS?HD, the osteomalacia observed in GHS?HD could be triggered when VDR?1,25D signaling crosses over a certain threshold.
In spite of the increased number of VDRs in GHS rats, the lower dose of 1,25D did not have an adverse effect on bone turnover and bone quality. However, the higher dose of 1,25D for 2 weeks was sufficient to severely delay or impair bone mineralization, resulting in a decrease in BMD and subsequent reduction in biomechanical properties. Thus, the more abundant VDRs in the GHS rats are biologically active. The mechanism(s) of this defect remains to be elucidated. The high levels of sOCN in GHS?HD indicate that osteoblasts in GHS exhibit a greater sensitivity to 1,25D than osteoblasts from SD, presumably as a function of their increased level of VDR. Further studies in GHS rats will need to focus on the effects of 1,25D on bone formation and resorption and to determine if there is a dose and time threshold at which 1,25D becomes detrimental.
